

PRESS RELEASE

Of interest to editors and journalists covering:
Business/Finance, Health, Medical, Biotech, Pharmaceuticals, TX Business

Dr. Tin-Chuen Yeung Named To Health Discovery Corporation Scientific Advisory Board

WACO, Texas - Nov. 25, 2003 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY), a biotechnology company which is focused on biomarker and pathway discovery for diagnostic markers and drug targets today announced the appointment of Dr. Tin-Chuen Yeung to its Scientific Advisory Board.

Dr. Yeung is a pharmacologist and experienced researcher in biotechnology. Besides his experience in research, he has substantial experience in intellectual property law, business development, technology evaluation and commercialization. He serves as an advisor to venture capital and start-up biotechnology companies throughout the United States.

Dr. Yeung is currently the Head of Strategic Development, Life Sciences, for the Chicago law firm Bell Boyd & Lloyd, LLC. He is admitted to practice patent law before the United States Patent Bar. At Bell Boyd & Lloyd, he is also with the Intellectual Property group responsible for patent prosecution in the areas of biotechnology, nanotechnology, agricultural biotechnology, pharmaceuticals, drug delivery technologies, medical devices and other life sciences. He also provides counseling to clients in patent filing strategies and management of intellectual property.

Prior to that, Dr. Yeung served as President of Everest International, Inc. consultants to Fortune 500 medical technology companies and start-up biotechnology companies. He also served as Director of Strategy & Business Development for the Biosciences Division at Baxter International, Inc., where he managed the strategic development for worldwide development, marketing and manufacturing of recombinant protein products. He also served as Director of Corporate Development for Baxter, responsible for management of Baxter's acquisitions, technology development, licensing, and strategic alliances.

Dr. Yeung worked for the G. D. Searle and NutraSweet Divisions of the Monsanto Company (MON:NYSE) for several years as a research scientist, and as manager of business ventures managing the evaluation and commercialization of new technologies. Prior to joining Monsanto, he was a research fellow at Harvard Medical School, Department of Pharmacology, studying the mechanisms of action and toxicity of anti-cancer drugs.

Dr. Yeung received Bachelor of Science in Biochemistry and Doctor of Philosophy in Pharmacology degrees from the State University of New York and a Master of Management from Northwestern University's Kellogg Graduate School of Management with concentrations in Finance, Marketing, and Management of Information Systems.

"It is rare to find in one individual the unique combination of a doctoral degree in pharmacology, an MBA, a biotechnology business development background, as well as, the expertise and knowledge to practice patent law before the United States Patent Bar. We are

extremely honored that Dr. Yeung with his vast and unique experience has agreed to become a member of our Scientific Advisory Board," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "Dr. Yeung will bring significant commercialization and patent experience and expertise to our team of Scientific Advisors as we move to create a commercial market for our patent protected biomarker discoveries used for diagnostic and pharmaceutical applications."

Dr. Yeung commented, "I believe that computational medicine and machine learning can significantly reduce both the time and the cost of developing new diagnostic tests and new therapies. I am looking forward to working with Dr. Barnhill and his team of experts at Health Discovery Corporation to achieve this goal."

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

MEDIA CONTACT:

Robert S. Braswell IV
of Health Discovery Corporation
+1-866-953-9031
Info@dwcell.com

#

[source of news = Health Discovery Corporation]
ref: http://www.send2press.com/2archive/2003/pr_03_1125-hdvy.txt

*Important Note to Media:
to reach the organization releasing this news, please contact:
Info@dwcell.com

If used for publication, please send specimen copy.

S2PRN/6c/ TX / Waco, Texas / Copr. (c) 2003 Send2Press.

This release was issued on behalf of the above organization by
Send2Press(TM), a unit of Neotropes(R). <http://www.Send2Press.com> .